Genomic and Epigenomic Features of Primary and Recurrent Hepatocellular Carcinomas
Xiaofan Ding(Chinese University of Hong Kong), Nathalie Wong(Chinese University of Hong Kong), Siu Ching Sze(Chinese University of Hong Kong), Mian He(Qingdao Agricultural University), Hui Chen(Zhongda Hospital Southeast University), Xin Wang(Jiangsu University), K Man(Chinese University of Hong Kong), Anthony W.H. Chan(Chinese University of Hong Kong), Kwan Man(University of Hong Kong), Paul B.S. Lai(Chinese University of Hong Kong), Qi Song(Chinese University of Hong Kong), Stephen L. Chan(Chinese University of Hong Kong)
Cited by 225
Related Papers
The consensus molecular subtypes of colorectal cancer
|Nature Medicine|2015|5.3k
Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade
|Journal of Clinical Oncology|2014|2.8k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k